Spark Therapeutics Inc.'s voretigene neparvovec is pending at FDA for treatment of a rare form of hereditary blindness and seems likely to become the first-ever gene therapy approval in the US. By default, it will then become the test case for how reimbursement and coverage policy works in the context of gene therapy.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?